Indian specialty pharma company developing complex generic and modified-release drug formulations, mainly for the US market.
Indian specialty pharma company developing complex generic and modified-release drug formulations, mainly for the US market.
Moat: narrow (IP / patents, process know-how). Formulation expertise in complex generics creates technical barriers, though competition from larger Indian generic makers is intense.
Headquarters: Navi Mumbai, India · Employees: 1,303
Size Rubicon Research (RUBICON.NS) is an India Health Care company (Biotechnology) with a market value of $2.94B, the 297th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,658 on 18 Nov 2026.
Performance Over six months the shares gained 68.5%, against -3.3% for the median peer and +3.8% for the India market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue grew 37.0% over the last twelve months (peer median +5.3%); the operating margin is 21.1% (peer median -0.7%).
Valuation It trades at 66.6× forward earnings against a peer median of 26.7× (2nd most expensive of 10).
Capital Return on invested capital runs 1.2 points above its cost of capital (18.7% WACC).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹21.0B | ₹17.5B | ₹12.7B | ₹8.48B | ₹3.91B |
| Revenue growth | — | +37% | +50% | +117% | — |
| Gross profit | ₹10.6B | ₹8.17B | ₹5.82B | ₹3.51B | ₹1.03B |
| EBITDA | ₹5.00B | ₹3.95B | ₹2.48B | ₹1.53B | ₹178M |
| Net income | ₹3.25B | ₹2.47B | ₹1.34B | ₹910M | -₹169M |
| Free cash flow | n/a | -₹553M | ₹575M | -₹633M | -₹1.35B |
| Capital expenditure | n/a | ₹2.29B | ₹702M | ₹561M | ₹445M |
| Total debt | ₹5.01B | ₹3.11B | ₹4.18B | ₹4.41B | ₹3.20B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Rubicon Research RUBICON.NS | $2.94B | +68% | +37% | 21% | 66.6× | n/a |
| Sun Pharmaceutical Industries SUNPHARMA.NS | $48.0B | -1% | +12% | 23% | 36.0× | 28.7% |
| Lupin LUPIN.NS | $9.67B | -14% | +24% | 24% | 21.0× | 8.8% |
| Amneal Pharmaceuticals AMRX | $7.62B | +79% | +9% | 16% | 19.2× | 17.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | RUBICON.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +11.5% | -4.6% | 4th highest of 21 |
| 6-month return | +68.5% | -3.3% | 5th highest of 21 |
| Distance from 52-week high | -12.7% | -31.6% | 4th highest of 21 |
| Revenue growth (TTM) | +37.0% | +5.3% | 3rd highest of 17 |
| Operating margin | 21.1% | -0.7% | 4th highest of 18 |
| Forward P/E | 66.6× | 26.7× | 2nd most expensive of 10 |
| ROIC minus cost of capital | +1.2 pp | -6.5 pp | 7th highest of 18 |
| EV / EBITDA | 55.4× | 12.8× | 2nd most expensive of 6 |
| Net debt / EBITDA | 0.4× | 1.1× | 3rd least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Rubicon Research RUBICON.NS | India | $2.94B | +68% | +37% | 21% | 66.6× | n/a | n/a |
| Denali Therapeutics DNLI | United States | $2.95B | -2% | n/a | -2,488% | n/a | n/a | n/a |
| Dyne Therapeutics DYN | United States | $2.97B | -10% | n/a | n/a | n/a | n/a | n/a |
| Telix Pharmaceuticals TLX.AX | Australia | $2.99B | -2% | +27% | -1% | 34.5× | n/a | n/a |
| ADMA Biologics ADMA | United States | $3.01B | +58% | +6% | 45% | 16.7× | -0.8% | +64.6% |
| XtalPi 2228.HK | Hong Kong | $2.87B | -34% | +4% | -127% | n/a | n/a | n/a |
| Bavarian Nordic A/S BAVA.CO | Denmark | $2.82B | +23% | -8% | 18% | 16.6× | -4.3% | +27.4% |
| Zai Lab 9688.HK | Hong Kong | $2.79B | +23% | 0% | -63% | n/a | n/a | n/a |
| Xeris Biopharma XERS | United States | $3.10B | +173% | +38% | 13% | 49.7× | 29.5% | +70.2% |
| Sunshine Lake Pharma 6887.HK | Hong Kong | $2.72B | -7% | +20% | -3% | n/a | n/a | n/a |
| Virbac VIRP.PA | France | $3.20B | -4% | +4% | 15% | 16.6× | 5.8% | +9.4% |
| Hualan Biological Engineering 002007.SZ | China | $3.20B | -17% | -11% | 17% | 26.7× | 15.8% | -1.8% |
| HLB 028300.KS | South Korea | $2.69B | -49% | +26% | -96% | n/a | n/a | n/a |
| MBX Biosciences MBX | United States | $2.65B | +70% | n/a | n/a | n/a | n/a | n/a |
| Enliven Therapeutics ELVN | United States | $3.30B | +7% | n/a | n/a | n/a | n/a | n/a |
| Caliway Biopharmaceuticals 6919.TW | Taiwan | $3.32B | -25% | -54% | -6,983% | n/a | n/a | n/a |
| Xencor XNCR | United States | $2.58B | +204% | +34% | -73% | n/a | n/a | n/a |
| Xiamen Amoytop Biotech 688278.SS | China | $2.56B | -27% | +18% | 27% | 15.0× | -0.6% | +36.0% |
| Iovance Biotherapeutics IOVA | United States | $3.46B | +111% | +51% | -61% | n/a | n/a | n/a |
| Beijing Tiantan Biological Products 600161.SS | China | $3.47B | -13% | -13% | 21% | 33.1× | 2.2% | +12.5% |
| Walvax Biotechnology 300142.SZ | China | $2.48B | -26% | -23% | 5% | 348.7× | 29.5% | -3.8% |